AC Immune First Half 2026 Financial and Corporate Update AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, provided a corporate and financial update for the half-year ended June 30, 2026. The period saw strong advances across the Company’s pipeline, with its partnered programs generating considerable milestone payments as […]
Transcript: Isabelle Abdou: Hi, and welcome to the Optimum Perspectives podcast. I’m Isabelle Abdou, and in this latest episode, we’ll be exploring women’s health, what’s really changing in the science, the capital behind it, and what still needs to shift. To explore it, I’m joined by three leading biotech executives and a seasoned healthcare investor. […]
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease Minoryx Therapeutics and Neuraxpharm Group, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male […]
Can you sum up what your company does in six? Not six minutes. Six words. That was a challenge set to attendees at One Nucleus’s Boston Bootcamp in the US in April. It was discussed at One Nucleus’s On Helix event in Cambridge a couple of weeks ago, and it really grabbed me. It grabbed […]
ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]
